Holen Sie sich die Stockscreener-App
16.16
3.46%
0.54
Schlusskurs vom Vortag:
$15.62
Offen:
$15.62
24-Stunden-Volumen:
138.10K
Relative Volume:
1.17
Marktkapitalisierung:
$264.83M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-9.0787
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
+4.12%
1M Leistung:
+52.02%
6M Leistung:
+109.33%
1J Leistung:
-7.13%
1-Tages-Spanne:
$15.41
$17.45
1-Wochen-Bereich:
$13.88
$17.80
52-Wochen-Spanne:
$5.231
$19.45
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
16.16 | 255.98M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma prices $110M common stock offering - MSN
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? - Yahoo Finance
Jobs Data: Can Sutro Biopharma Inc deliver alpha2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Sutro Biopharma prices $110 million common stock offering By Investing.com - Investing.com Nigeria
Performance Recap: Why is Sutro Biopharma Inc stock going downJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sutro Biopharma Highlights ADC Platform in New Presentation - TipRanks
Sutro Biopharma Signs Underwriting Agreement With Leerink Partners and TD Securities (USA) - TradingView
Sutro Biopharma (STRO) Sees Joint Management in Upcoming Offerin - GuruFocus
Sutro Biopharma prices $110 million common stock offering - Investing.com
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering - Stock Titan
Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Aug Sectors: Why is Sutro Biopharma Inc stock going downTrade Risk Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation - Sahm
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 30.5% - MarketBeat
Pullback Watch: Is Sutro Biopharma Inc in a bullish channelWeekly Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Macro Review: Should I invest in Sutro Biopharma Inc before earningsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Options Flow: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Sutro Biopharma (STRO) soars 5.9%: Is further upside left in the stock? - MSN
Winners Losers: Does MFS Government Markets Income Trust have a sustainable dividendEntry Point & Short-Term Trading Alerts - baoquankhu1.vn
Trade Recap: Is Adlai Nortye Ltd Depositary Receipt part of any ETF2025 Geopolitical Influence & Reliable Price Breakout Alerts - baoquankhu1.vn
Panic Selling: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Sutro Biopharma (NASDAQ:STRO) Upgraded to “Market Outperform” at Citizens Jmp - Defense World
STRO Receives Upgraded Analyst Rating from Citizens | STRO Stock News - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Market Outperform" at Citizens Jmp - MarketBeat
Citizens Upgrades Sutro Biopharma (STRO) - Nasdaq
Citizens JMP Upgrades Sutro Biopharma(STRO.US) to Buy Rating, Announces Target Price $23 - 富途牛牛
Citizens upgrades Sutro Biopharma stock rating to Market Outperform By Investing.com - Investing.com Canada
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 27.8% in December - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO) and Molina Healthcare (MOH) - The Globe and Mail
BofA Securities Maintains Sutro Biopharma(STRO.US) With Sell Rating, Maintains Target Price $8 - 富途资讯
Aug Decliners: Is Sutro Biopharma Inc stock a value trapQuarterly Portfolio Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Sutro Biopharma: Streamlined strategy and advanced ADC pipeline drive clinical progress and differentiation - TradingView — Track All Markets
Sutro Biopharma: Accelerated ADC pipeline and strategic focus drive clinical progress and financial stability - TradingView — Track All Markets
Stock Recap: Is Sutro Biopharma Inc a potential multi baggerBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Volume Summary: Can Sutro Biopharma Inc reach resistance levels soonJuly 2025 Price Swings & Weekly Market Pulse Alerts - baoquankhu1.vn
Merger Talk: Why is Sutro Biopharma Inc stock going downQuarterly Profit Report & Proven Capital Preservation Tips - baoquankhu1.vn
Short Squeeze: Will Sutro Biopharma Inc stock benefit from sector rotationPortfolio Risk Summary & Detailed Earnings Play Alerts - Bộ Nội Vụ
Why millennials buy Sutro Biopharma Inc. (S09) stockMarket Trend Report & Fast Exit and Entry Strategy Plans - Улправда
Is Sutro Biopharma Inc. stock supported by strong cash flowsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - Улправда
Is Sutro Biopharma Inc. stock a buy for dividend growth2025 Bull vs Bear & Precise Buy Zone Identification - Улправда
Is Sutro Biopharma Inc. stock undervalued vs historical averagesProfit Target & Risk Controlled Daily Plans - Улправда
Will Sutro Biopharma Inc. stock benefit from sector rotationInflation Watch & Consistent Return Strategy Ideas - ulpravda.ru
How risky is Sutro Biopharma Inc. stock nowJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - ulpravda.ru
What momentum indicators show for Sutro Biopharma Inc. stockPortfolio Risk Summary & Free Safe Capital Growth Stock Tips - ulpravda.ru
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
STRO: HC Wainwright Raises Price Target by 400% Today | STRO Sto - GuruFocus
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Growth Report: What consensus target says about Sutro Biopharma Inc S09 stockQuarterly Trade Report & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chung Jane | Chief Executive Officer |
Dec 12 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
14,785 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Oct 15 '25 |
Buy |
0.80 |
17,000 |
13,607 |
71,832 |
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):